why choose us

300×250 Ad Slot

Drug FDA Status

Showing 100 of 196 result(s) (Page 10 of 20)
Drug Name: Datroway

Active Ingredient: datopotamab deruxtecan-dlnk

Approval Date: 2025-01-17

Description: To treat unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease
Drug Trials Snapshot

Drug Name: Alhemo

Active Ingredient: concizumab-mtci

Approval Date: 2024-12-20

Description: For routine prophylaxis to prevent bleeding episodes in hemophilia A and B

Drug Name: Alyftrek

Active Ingredient: vanzacaftor, tezacaftor, and deutivacaftor

Approval Date: 2024-12-20

Description: To treat cystic fibrosis

Drug Name: Tryngolza

Active Ingredient: olezarsen

Approval Date: 2024-12-19

Description: To treat familial chylomicronemia syndrome
Drug Trials Snapshot

Drug Name: Ensacove

Active Ingredient: ensartinib

Approval Date: 2024-12-18

Description: To treat non-small cell lung cancer

Drug Name: Crenessity

Active Ingredient: crinecerfont

Approval Date: 2024-12-13

Description: To treat classic congenital adrenal hyperplasia 
Press Release

Drug Name: Unloxcyt

Active Ingredient: cosibelimab-ipdl

Approval Date: 2024-12-13

Description: To treat cutaneous squamous cell carcinoma

Drug Name: Bizengri

Active Ingredient: zenocutuzumab-zbco

Approval Date: 2024-12-04

Description: To treat non-small cell lung cancer and pancreatic adenocarcinoma 

Drug Name: Iomervu

Active Ingredient: iomeprol

Approval Date: 2024-11-27

Description: For use as a radiographic contrast agent

Drug Name: Rapiblyk

Active Ingredient: landiolol

Approval Date: 2024-11-22

Description: To treat supraventricular tachycardia

300×250 Ad Slot